Teladoc One is a model of care delivered as a single, predictive and adaptive experience to drive better health outcomes and address the rising total cost of care
Multidisciplinary care teams, paired with always-on AI support, deliver and guide every step of care
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the pioneer and global leader in virtual care, today announced Teladoc One — a fundamentally new model of virtual care. Teladoc One begins with the person. It addresses the industry's longstanding challenge of fragmented care, where solutions have been built to address one disease at a time rather than dynamically supporting a person's entire health needs.
Teladoc One continuously adapts to each individual, with Teladoc Health care teams delivering and coordinating care across virtual settings and in partnership with a member's trusted local providers. With it, Teladoc Health is advancing a vision in which care is no longer fragmented, but connected, adaptive and deeply accountable for outcomes.
Teladoc One builds on the company’s strong foundation as the nation's largest multi-specialty virtual care practice, with decades of clinical and behavioral data and expertise from delivering more than 100 million visits across primary care, mental health, chronic illness and acute care.
Drawing on the largest unified data ecosystem in virtual healthcare, Teladoc Health's Pulse intelligence engine pairs clinical history with available context from claims, pharmacy, device, medical record, engagement and eligibility data — helping Teladoc Health care teams identify needs earlier, intervene at the right time, improve follow-up, better support specialty referrals and drive better outcomes. Teladoc One is the result of two years rebuilding the technical foundation to bring those assets together.
"Three in four Americans manage at least one chronic disease, driving approximately $4.7 trillion of spending a year — costs that employers and health plans can’t sustain," said Kelly Bliss, President of U.S. Group Health at Teladoc Health. "The industry’s current approach of treating one disease at a time isn’t the answer. Teladoc One changes that. We’ve applied industry-leading intelligence and multidisciplinary care teams to deliver highly personalized care at scale. Importantly for our buyers, Teladoc One raises the bar on accountability, delivering a model that answers to outcomes.”
The average U.S. adult spends eight hours each month coordinating healthcare, the equivalent of a full workday. In addition, the average adult uses six different health-related apps on a regular basis. Teladoc One helps solve this challenge by treating every patient as a population of one. The model supports personalized care pathways, with new capabilities that match patients to the right level of care, optimized for cost and need. As a result, patients don’t have to spend hours deciding what to do and where to go next, and plan sponsors don’t have to buy yet another solution to simply connect patients across their ecosystem. Under the Teladoc One care model, care teams anticipate a patient’s unique needs and deliver or route care appropriately, whether that’s to a Teladoc Health clinician, or a member’s local trusted provider. When in-person care is needed, Teladoc Health care teams don't just refer patients, they actively coordinate it across settings to ensure follow-through.
What's new with Teladoc One
Backed by Teladoc Health's clinical quality and rigor, Teladoc One designs a healthcare ecosystem around the person. Through this model, care adapts to each individual using technology and data. Patients are supported by:
A multidisciplinary virtual care team spanning licensed clinicians, certified health coaches, registered dietitians, mental health therapists and specialists who support every step of care.A human care guide who keeps them on track with their care plan and escalates to other members of the care team as necessary, coordinating with in-network primary care physicians and specialists, exchanging data and ensuring follow-through.Always-on AI support that works in concert with the care team and keeps members supported and engaged between human touchpoints — drawing on a member’s history and preferences to check in, send reminders, help with scheduling and gather information that's surfaced to the human care team.
“Teladoc One represents the next evolution of healthcare, where care is no longer fragmented, but connected, adaptive and more accountable for outcomes,” said Dr. Ethan Berke, Chief Medical Officer at Teladoc Health. "This proactive, always-on model gives us the ability to care for each person holistically in ways we couldn't before."
Teladoc One is designed to deliver superior outcomes, helping improve health while reducing total cost of care through earlier intervention, better coordination and more effective use of clinical resources. Lower total medical costs are driven by smarter medication management, optimized care site selection, avoidance of unnecessary referrals, improved condition control and meaningful reductions in ER visits and hospitalizations.
Teladoc One moves beyond condition-specific programs to deliver personalized, outcome-based, intelligent care journeys, addressing the full spectrum of needs, from prevention to the treatment of complex conditions. As a part of this model, Teladoc Health is placing 100% of its fees at risk, linking payment directly to performance towards achievement of clinical outcome measures and total cost of care improvement for a full population. By aligning program economics with validated cost reductions, Teladoc Health creates a true partnership model with its clients.
Data consistently show that Teladoc Health’s connected care model delivers more value to customers. Teladoc Health’s customers increasingly turn to the company to resolve a wider range of care needs. In fact, 67% of Teladoc Health clients have two or more products — a testament to the growing value of integrated care. Furthermore, a recent study of more than 29,000 Teladoc Health members enrolled in multiple chronic care programs found that when chronic care and mental health are combined, members have significantly greater reduction in blood sugar and more weight loss.
The launch is part of Teladoc Health’s strategy to enhance its integrated care offerings and deliver greater value to customers. The company recently unveiled new partnerships with the National Basketball Players Association, Walmart and Instacart, and expanded its flagship 24/7 Care service, which can now address a significantly wider spectrum of health needs.
Teladoc One was developed in partnership with select clients, first targeting populations with cardiometabolic health needs, with the ability to expand to additional populations over time. Programs under the Teladoc One model will launch with select clients in September 2026, with broader availability beginning January 2027.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Teladoc One Programs under the Teladoc One model will launch with select clients in September 2026, with broader... Teladoc Health Teladoc One builds on the Teladoc Health's strong foundation as the nation's largest multi-specialty...
Teladoc (TDOC - Free Report) ended the recent trading session at $9.65, demonstrating a +2.33% change from the preceding day's closing price. This change outpaced the S&P 500's 0.19% loss on the day. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Shares of the telehealth services provider have appreciated by 16.85% over the course of the past month, outperforming the Medical sector's gain of 6.06%, and the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2026. The company is predicted to post an EPS of -$0.24, indicating a 26.32% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $614.69 million, showing a 2.72% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.92 per share and a revenue of $2.51 billion, signifying shifts of +19.3% and -0.92%, respectively, from the last year.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Teladoc is carrying a Zacks Rank of #2 (Buy).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
July 15, 2026 16:05 ET | Source: Teladoc Health, Inc.
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release second quarter 2026 results on Wednesday, July 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day.
Conference Call Details
The conference call can be accessed by dialing 833-461-5787 for U.S. participants and using the meeting ID # 478 236 923.
For international participants, please visit the following link for global dial-in numbers, using the same meeting ID # 478 236 923: https://help.events.q4inc.com/eahc/international-dial-in-numbers. A live audio webcast will also be available online at https://ir.teladoc.com/news-and-events/events-and-presentations/.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Teladoc (TDOC - Free Report) closed at $9.21 in the latest trading session, marking a +1.54% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.81% for the day. Elsewhere, the Dow saw an upswing of 0.27%, while the tech-heavy Nasdaq appreciated by 1.3%.
The telehealth services provider's shares have seen an increase of 29.02% over the last month, surpassing the Medical sector's gain of 7% and the S&P 500's gain of 1.13%.
The upcoming earnings release of Teladoc will be of great interest to investors. In that report, analysts expect Teladoc to post earnings of -$0.24 per share. This would mark a year-over-year decline of 26.32%. In the meantime, our current consensus estimate forecasts the revenue to be $614.69 million, indicating a 2.72% decline compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.92 per share and revenue of $2.51 billion. These totals would mark changes of +19.3% and -0.92%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Teladoc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Teladoc is currently a Zacks Rank #3 (Hold).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 96, positioning it in the top 40% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Teladoc Health Inc. (NYSE:TDOC) shares are trending Wednesday as investors take a fresh look at the company.
Teladoc Health stock is trending lower. Why is TDOC stock retreating? For a cash-pay price of $89 per visit, Walmart customers can access Teladoc’s clinical practice through the platform, including 24/7 care for common conditions, dermatology consultations, and one-on-one nutrition support. Prescriptions, if needed, can be sent to a pharmacy including Walmart, where same-day delivery is available in many locations.
“Walmart is where millions of Americans already go for everyday needs, and now, getting care from Teladoc Health can be part of that same experience,” said Kelly Bliss, Teladoc Health’s President of U.S. Group Health. “By removing friction and meeting people where they are, virtual care becomes something people choose first, not just something they can access.”
The announcement builds on an earlier integration — in January, Teladoc’s BetterHelp mental health offering launched on Walmart’s Better Care Services platform, further expanding the companies’ collaboration.
Teladoc Shares FallTDOC Price Action: At the time of publication, Teladoc shares are trading 1.94% lower at $9.33, according to data from Benzinga Pro.
Image: Courtesy of Teladoc
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
As virtual care evolves, choosing between Hims & Hers Health (HIMS +4.02%) and Teladoc Health (TDOC +0.98%) depends on whether you prefer explosive growth in consumer subscriptions or established, large-scale institutional healthcare partnerships.
Hims & Hers focuses on direct-to-consumer wellness solutions for specific conditions, such as hair loss and weight management. Teladoc provides a comprehensive virtual care platform for employers and health plans. While both lead in digital health, their paths to profitability and market strategies represent very different investment opportunities for 2026.
The case for Hims & Hers HealthHims & Hers operates a direct-to-consumer digital health platform within the broader healthcare stocks category. It provides personalized treatment plans for hair care, mental health, and weight loss, serving nearly 2.6 million subscribers as of Q1 2026. The company is currently scaling its operations through the pending acquisition of Eucalyptus and recently secured a $400 million receivables facility with JPMorgan Chase (JPM +1.43%) to support its pharmacy operations.
In FY 2025, the company reported revenue of nearly $2.3 billion, representing approximately 59.0% growth from the previous fiscal year. It achieved net income of approximately $128.4 million during this period, a slight increase from the prior year. This resulted in a net margin, or the percentage of revenue remaining after all expenses, of roughly 5.5%.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 2.1x. This ratio measures a company's total debt against the value of its ownership interest. The current ratio, which measures the ability to cover short-term liabilities with short-term assets, stands at nearly 1.9x.
The case for Teladoc HealthTeladoc serves over 100 million members globally through its Integrated Care and BetterHelp segments. It recently expanded its distribution through a strategic partnership with Walmart (WMT 1.06%) to integrate virtual care into retail platforms. However, the company remains dependent on a limited number of large clients, with its top five customers historically accounting for nearly 19% of total revenue.
During FY 2025, Teladoc reported revenue of approximately $2.5 billion, which was a slight decrease of nearly 1.5% from the prior year. The company recorded a net loss of close to $200.3 million for the fiscal year, though this narrowed significantly from the $1.0 billion net loss recorded in the year prior. This performance led to a negative net margin of roughly 7.9% as the company continues to work toward consistent profitability.
According to the December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x. The current ratio is nearly 2.7x, indicating a strong ability to meet immediate financial obligations.
Risk profile comparisonHims & Hers Health faces significant regulatory pressure regarding compounded GLP-1s and peptides, with the FDA indicating potential restrictions on certain ingredients. The company is also navigating a potential investigation by the DOJ and HHS regarding its business practices. Furthermore, the rapid integration of acquisitions such as Eucalyptus poses operational risks that could undermine the company's ability to maintain its growth trajectory.
Teladoc Health deals with heavy customer concentration, where the loss of a major health plan client could materially damage its financials. The BetterHelp segment has struggled with declining paying users, adding pressure to the company's overall growth. Teladoc also faces intense competition from established giants like Amazon (AMZN +0.61%) and Alphabet, (GOOG +2.44%) (GOOGL +1.87%) which are increasingly entering the virtual care market with their own digital health initiatives.
Valuation comparisonTeladoc Health offers a lower P/S ratio, while Hims & Hers Health carries a higher forward P/E due to its rapid growth.
MetricHims & Hers HealthTeladoc HealthSector BenchmarkForward P/E78.9x59.4x389.1xP/S ratio3.5x0.7xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Consumers have more choices than ever when it comes to healthcare providers, like Hims & Hers and Teladoc. The companies provide different services, but it’s useful to compare them because they represent two different strategies that appeal to investors with different goals.
Like many consumer wellness platforms, Hims & Hers targets personal health needs, particularly those that are repetitive in nature and lend themselves to subscription services, such as sexual health and weight loss. Compounded GLP-1 medications have been an especially lucrative offering for the company. Hims & Hers trades at a premium valuation, which may worry investors due to potential regulatory issues and increasing market competition.
Teladoc provides virtual healthcare visits, connecting patients to a network of medical professionals. The company makes money from employers and healthcare plans that pay subscription fees. Virtual doctor visits skyrocketed during the pandemic, but as clinics and physicians’ practices reopened, the stock plunged. But most of Teladoc’s troubles stem from its acquisition of Livongo and expenses related to its BetterHelp brand. The good news is its very low valuation and turnaround strategy, which is starting to pay off.
Investors who are willing to invest in bargain stocks with the hope of a big future payoff may find Teladoc’s stock compelling. But Hims & Hers remains a steady growth engine, generating predictable revenue from its direct-to-consumer subscription services. For this reason, I’d choose Hims & Hers.
July 03, 2026 16:30 ET | Source: Teladoc Health, Inc.
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.
Effective July 1, 2026, in connection with commencing employment as Head of Product of BetterHelp, David Packles was granted an award of restricted stock units covering 50,000 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
After years of lagging broader equities, Teladoc Health (TDOC +1.10%) is finally bouncing back. The company's shares are up by 28% to date, while the S&P 500 has climbed just 9%. The telemedicine specialist still has plenty of work to do, but could it finally be on the road to full recovery? Let's see whether Teladoc can maintain the momentum it has had this year.
Why Teladoc is bouncing back At first glance, Teladoc doesn't seem to be doing that much better. In the first quarter, the company's revenue declined 2% year over year to $613.8 million. Sales from its BetterHelp virtual therapy division fell 9% year over year to $218.4 million, while the number of paying users on BetterHelp also fell 9%. Further, Teladoc remains unprofitable. It posted a net loss per share of $0.36, which, in fairness, was much better than the $0.53 loss per share it recorded in the year-ago period.
Image source: The Motley Fool.
Still, overall, Teladoc's financial results look mediocre. Why is the stock performing well? Part of the answer is that the market is paying attention to several developments that could help fix some of the company's issues. Consider BetterHelp, which was once Teladoc's biggest growth driver. For years, the company tried to get health insurance coverage for this unit. It has finally done so in many U.S. states thanks to an acquisition. Teladoc is seeing clear evidence that this is helping.
As the company reported, virtual therapy users who benefit from insurance coverage averaged about 20% more sessions than cash-paying patients in their first 90 days. Teladoc also expects to end 2026 with an annual run rate of at least $125 million for the company's BetterHelp insurance-covered sessions -- a meaningful improvement over the $75 million it had as of the end of the first quarter. Teladoc is also making progress elsewhere.
Notably, the company's international expansion is still going well. In the first quarter, Teladoc's international revenue grew by 17% year over year to $122.3 million. Meanwhile, Teladoc is implementing various artificial intelligence (AI)-powered initiatives across its business that could have a meaningful impact over the long run. For instance, the company has reduced the administrative work that BetterHelp's therapists do through AI-assisted documentation, allowing them to spend more time focusing on patients.
This is good for everyone involved. Teladoc could continue to see much-improved financial results and stock price performance if it can keep launching initiatives like these.
Today's Change
(
1.10
%) $
0.10
Current Price
$
9.20
Although Teladoc has addressed some of the issues it has encountered in recent years, it isn't out of the woods just yet. Here are several things that could go wrong for the telemedicine company. First, although it is making some progress with BetterHelp, thanks to third-party coverage, the virtual therapy space is very competitive. That's one reason why Teladoc faced -- in the company's own words -- "mounting pressure" within its direct-to-patient cash-paying virtual therapy business.
Insurance coverage is helpful, but even with that, BetterHelp's upside might be limited by the increasingly competitive nature of this industry. Second, although Teladoc's international revenue has been growing faster than the rest of the business, the company's global ambitions may eventually backfire. Managing legal and regulatory requirements, insurance rules and regulations, prescriptions, and many other matters that Teladoc engages in across different countries could turn into a nightmare.
We might see Teladoc's expenses rise significantly as the company continues its expansion plans abroad. As a result, it may be difficult for the company to turn profitable. Lastly, although Teladoc's AI-related work looks promising, it is unlikely to give it a significant advantage over most of its competitors, many of whom are also likely implementing similar strategies. The bottom line is that Teladoc has yet to demonstrate it can perform consistently, while it still faces significant headwinds. So, even with the progress it has made, its shares look fairly risky. Investors should keep that in mind before initiating a position. And only those comfortable with volatility should consider doing so.
Teladoc (TDOC - Free Report) ended the recent trading session at $8.48, demonstrating a -2.42% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.79% for the day. At the same time, the Dow added 0.26%, and the tech-heavy Nasdaq gained 1.52%.
Coming into today, shares of the telehealth services provider had gained 9.86% in the past month. In that same time, the Medical sector gained 7.53%, while the S&P 500 lost 1.82%.
The investment community will be closely monitoring the performance of Teladoc in its forthcoming earnings report. On that day, Teladoc is projected to report earnings of -$0.24 per share, which would represent a year-over-year decline of 26.32%. In the meantime, our current consensus estimate forecasts the revenue to be $614.69 million, indicating a 2.72% decline compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.92 per share and revenue of $2.51 billion. These totals would mark changes of +19.3% and -0.92%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Teladoc. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Teladoc currently has a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 89, positioning it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizations SURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales.
Teladoc (TDOC - Free Report) closed at $7.81 in the latest trading session, marking a +1.56% move from the prior day. This change outpaced the S&P 500's 0.1% loss on the day. Elsewhere, the Dow saw an upswing of 0.35%, while the tech-heavy Nasdaq depreciated by 0.43%.
The telehealth services provider's stock has climbed by 16.69% in the past month, exceeding the Medical sector's gain of 1.97% and the S&P 500's loss of 1.34%.
The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.24, reflecting a 26.32% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $614.69 million, reflecting a 2.72% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.92 per share and a revenue of $2.51 billion, signifying shifts of +19.3% and -0.92%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Teladoc is currently a Zacks Rank #3 (Hold).
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 96, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Teladoc (TDOC - Free Report) ended the recent trading session at $7.57, demonstrating a +1.47% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The telehealth services provider's stock has climbed by 17.48% in the past month, exceeding the Medical sector's gain of 4.28% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of Teladoc in its upcoming release. The company is expected to report EPS of -$0.24, down 26.32% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $614.69 million, indicating a 2.72% downward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and a revenue of $2.51 billion, representing changes of +19.3% and -0.92%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Teladoc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.97% higher within the past month. Teladoc currently has a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 109, placing it within the top 45% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Analysts on Wall Street project that Teladoc (TDOC - Free Report) will announce quarterly loss of -$0.32 per share in its forthcoming report, representing a decline of 68.4% year over year. Revenues are projected to reach $612.3 million, declining 2.7% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Teladoc metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenues by Segment- BetterHelp' to reach $217.49 million. The estimate indicates a year-over-year change of -9.3%.
Analysts expect 'Revenues by Segment- Integrated Care' to come in at $391.80 million. The estimate points to a change of +0.6% from the year-ago quarter.
Analysts predict that the 'Revenues by Segment- BetterHelp- Therapy Services' will reach $215.64 million. The estimate indicates a year-over-year change of -8%.
The consensus estimate for 'Revenues by Segment- BetterHelp- Other Wellness Services' stands at $4.21 million. The estimate suggests a change of -22.9% year over year.
The average prediction of analysts places 'Revenue by Type- Access fees' at $506.54 million. The estimate indicates a year-over-year change of -3.7%.
Analysts' assessment points toward 'Revenue by Type- Other' reaching $106.74 million. The estimate suggests a change of +3% year over year.
It is projected by analysts that the 'U.S. Integrated Care Members' will reach 99.14 million. The estimate is in contrast to the year-ago figure of 102.50 million.
Based on the collective assessment of analysts, 'Adjusted EBITDA- BetterHelp' should arrive at $2.88 million. Compared to the present estimate, the company reported $7.71 million in the same quarter last year.
The collective assessment of analysts points to an estimated 'Adjusted EBITDA- Integrated Care' of $52.28 million. The estimate is in contrast to the year-ago figure of $50.38 million.
View all Key Company Metrics for Teladoc here>>>
Shares of Teladoc have demonstrated returns of +13.8% over the past month compared to the Zacks S&P 500 composite's +12.8% change. With a Zacks Rank #3 (Hold), TDOC is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 (“First Quarter 2026”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2025 (“First Quarter 2025”).
Teladoc Health (NYSE:TDOC) reported mixed first-quarter financial results that have shares falling on Wednesday after market close.
Here are the key highlights.
• Teladoc Health stock is among today’s weakest performers. Why is TDOC stock falling?
Teladoc reported first-quarter revenue of $613.8 million, down 2% year-over-year. The revenue total beat a Street consensus estimate of $610.9 million, according to data from Benzinga Pro.
Integrated Care revenue was $395.4 million in the quarter, up 2% year-over-year.
BetterHelp revenue was $218.4 million in the quarter, down 9% year-over-year.
The company reported a net loss of 36 cents per share, missing a Street consensus estimate of a loss of 33 cents per share.
Adjusted EBITDA margins were 14.2% and 0.9% for Integrated Care and BetterHelp, respectively.
"We delivered a good start to 2026, with first quarter consolidated revenue and adjusted EBITDA exceeding the midpoint of our guidance ranges, and our full-year outlooks for both segments remain on track," Teladoc CEO Chuck Divita said.
Divita said Integrated Care saw "solid results" in the quarter, while BetterHelp made "meaningful progress" with increasing insurance acceptance.
What's Next for TeladocThe company is guiding for second-quarter revenue of $597 million to $626 million, versus a Street consensus estimate of $623.67 million.
Guidance for earnings for the second quarter is a loss of 30 cents to a loss of 20 cents per share, versus a Street estimate of a loss of 23 cents per share.
For the full fiscal year, Teladoc narrowed its guidance for revenue from a prior range of $2.470 to $2.587 billion to a new range of $2.481 billion to $2.576 billion. The Street consensus estimate is $2.509 billion.
The company also narrowed its full-year earnings per share guidance, now expecting a loss of $1.05 to a loss of 75 cents per share, versus a previous range of a loss of $1.10 to a loss of 70 cents per share. The Street estimate is a loss of 89 cents for the full year.
"We remain focused on disciplined execution across our strategic priorities, including key investments in product innovation, technology, and our clinical model," Divita said. "We see a meaningful opportunity to build on the unique strengths of our platform to deliver measurable and differentiated value for our clients and members and to return the business to growth."
Divita said the company remains committed to "driving long-term value for all stakeholders."
Teladoc Health Stock Price ActionTeladoc stock is down 5.6% to $5.62 in after-hours trading on Wednesday versus a 52-week trading range of $4.40 to $9.77.
Photo: courtesy of Teladoc.
Market News and Data brought to you by Benzinga APIs
Teladoc (TDOC - Free Report) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -13.82%. A quarter ago, it was expected that this telehealth services provider would post a loss of $0.19 per share when it actually produced a loss of $0.14, delivering a surprise of +26.32%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Teladoc, which belongs to the Zacks Medical Services industry, posted revenues of $613.85 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.25%. This compares to year-ago revenues of $629.37 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Teladoc shares have lost about 14.3% since the beginning of the year versus the S&P 500's gain of 4.3%.
What's Next for Teladoc?While Teladoc has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Teladoc was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.23 on $624.65 million in revenues for the coming quarter and -$0.89 on $2.51 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Aclarion, Inc. (ACON - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $1.55 per share in its upcoming report, which represents a year-over-year change of +83.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Aclarion, Inc.'s revenues are expected to be $0.03 million, up 50% from the year-ago quarter.
While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teladoc Health stock is taking a hit today. Why is TDOC stock dropping? Teladoc Q1 Results: Revenue Dips As Earnings Miss EstimatesThe company reported first-quarter revenue of $613.8 million (down 2%) and a net loss of 36 cents per share, which missed expectations for a loss of 33 cents. Management also guided second-quarter EPS to a loss of 30 cents to a loss of 20 cents, alongside revenue of $597 million to $626 million.
Teladoc also narrowed full-year revenue guidance to $2.481 billion to $2.576 billion from the prior $2.470 billion to $2.587 billion range, keeping the focus on whether losses can compress fast enough to justify a re-rate.
Teladoc Stock: Critical Levels To WatchTeladoc is still trading in the lower half of its 52-week range ($4.40 to $9.77), which keeps the longer-term chart in "repair mode" after earlier breakdowns. The stock is trading 8.4% below its 20-day simple moving average (SMA) and 13.9% below its 100-day SMA, a setup that leans bearish for trend followers because rallies haven't been strong enough to reclaim key trend lines.
The moving average convergence divergence (MACD), a trend/momentum measure, is above its signal line with a positive histogram, which points to improving momentum underneath the tape even as price sits below major averages. In everyday terms, MACD being above the signal line means downside pressure is easing compared with recent weeks, but it doesn't confirm a full trend reversal by itself.
The longer view remains heavy: the stock is down 17.25% over the past 12 months, which fits with a market that has repeatedly sold rallies. The death cross that occurred in December 2025 (50-day SMA below the 200-day SMA) reinforces that the dominant trend has been lower, so traders often look for proof of sustained strength before trusting bounces.
Key Resistance: $6.00 — a level where prior rallies have struggled to push through. Key Support: $4.50 — an area where buyers have tended to show up near recent lows. TDOC Stock Price Activity In Premarket TradingTDOC Stock Price Activity: Teladoc Health shares were down 12.09% at $5.23 during pre-market trading on Thursday, according to Benzinga Pro data.
Image: Courtesy of Teladoc
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Hims & Hers is expanding into weight loss and specialty care, including FDA-approved GLP-1 therapies.Hims & Hers is pushing AI, data infrastructure and tailored treatments to scale and expand margins.TDOC's Integrated Care and BetterHelp insurance shift support steadier growth and margin expansion. Digital healthcare continues to evolve across both direct-to-consumer and enterprise-focused platforms, with Hims & Hers Health, Inc. (HIMS - Free Report) and Teladoc Health, Inc. (TDOC - Free Report) representing two distinct approaches to technology-enabled care. HIMS operates a consumer-first platform that connects individuals to licensed providers, enabling telehealth consultations, prescription fulfillment and access to personalized treatments. In contrast, TDOC is a global virtual care platform serving employers, health plans and health systems through integrated, technology-enabled care solutions. The two companies operate at different points within the healthcare ecosystem, reflecting contrasting models within the broader shift toward digitally enabled care delivery.
While Hims & Hers focuses on delivering personalized, consumer-centric health and wellness solutions (including telehealth services, digital prescriptions and ongoing care management), Teladoc Health emphasizes a comprehensive, multi-channel care model spanning preventive, primary, chronic and mental healthcare across both B2B and direct-to-consumer channels.
As digital health adoption expands, this contrast highlights two differentiated strategies and raises the question of which model may offer greater long-term opportunity. Let’s take a closer look.
Stock Performance & Valuation: HIMS vs. TDOCHIMS (down 0.4%) has underperformed TDOC (up 10.8%) over the past three months. In the past year, Hims & Hers stock has lost 27.1% compared with Teladoc Health’s decline of 14.8%.
Image Source: Zacks Investment Research
Meanwhile, HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 2X, below its median of 2.6X over the past five years. TDOC’s forward P/S multiple sits at 0.4X, below its five-year median of 1.2X. HIMS and TDOC both appear to be cheap when compared with the Zacks Medical sector’s average of 2.4X. Currently, Hims & Hers and Teladoc Health stocks have a Value Score of C and B, respectively.
Image Source: Zacks Investment Research
Factors Driving Hims & Hers StockHims & Hers’ growth is being driven by its rapid expansion into high-demand treatment categories, particularly weight loss and specialty care. The company’s collaboration with Novo Nordisk and broader shift toward FDA-approved GLP-1 therapies significantly strengthen its positioning in a fast-growing market, while improving affordability and access through its platform. This not only drives new customer acquisition but also deepens engagement through integrated care offerings, such as provider access and ongoing clinical support.
HIMS’ technology-led approach, particularly its increasing investment in AI and personalized care, is enhancing its competitive differentiation. With new leadership focused on AI and continued funding directed toward data infrastructure, diagnostics and tailored treatments, Hims & Hers is building a scalable platform that improves care delivery while expanding margins over time.
International expansion and strategic acquisitions are further accelerating its growth trajectory. Moves such as the acquisition of Eucalyptus and expansion into markets like Canada and Europe highlight a deliberate push to replicate its consumer health model globally. Backed by strong subscriber growth and rising demand for personalized digital healthcare, these initiatives position Hims & Hers to scale its platform across geographies and capture a larger share of the global digital health market.
Factors Driving Teladoc Health StockTeladoc Health’s Integrated Care platform is benefiting from a shift toward more comprehensive, multi-condition healthcare delivery. Clients are increasingly moving away from fragmented point solutions and toward bundled offerings that address chronic conditions, mental health and primary care in a unified model. This plays directly to TDOC’s scale and breadth, supporting higher engagement and steady growth in areas like chronic care enrollment and enterprise adoption.
The evolution of its mental health business, particularly the transition of BetterHelp toward insurance-based access, is another key driver. Expanding insurance coverage is improving conversion rates, engagement and user retention by lowering affordability barriers, while also stabilizing performance in a segment that previously relied heavily on cash-pay users. Early traction in insurance-backed sessions and broader geographic rollout indicate a more durable and scalable growth model over time.
Ongoing investments in AI, data infrastructure and product innovation are strengthening Teladoc Health’s competitive positioning. Platforms like its AI-powered intelligence engine and enhanced care delivery systems are enabling more personalized, efficient care while improving provider productivity and outcomes. These capabilities, combined with cost discipline and operational improvements, support margin expansion and position TDOC to deliver more differentiated, technology-driven virtual care solutions at scale.
Comparing EPS Projections: HIMS vs. TDOCThe Zacks Consensus Estimate for HIMS’ 2026 earnings per share (EPS) suggests a 5.7% improvement from 2025.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TDOC’s 2026 loss per share implies an improvement of 21.9% from 2025.
Image Source: Zacks Investment Research
Price Target: Hims & Hers vs. Teladoc HealthBased on short-term price targets offered by 14 analysts, the average price target for Hims & Hers is $26.79, implying an increase of 1.8% from the last close.
Image Source: Zacks Investment Research
Based on short-term price targets offered by 21 analysts, the average price target for Teladoc Health is $7.09, implying an increase of 19.2% from the last close.
Image Source: Zacks Investment Research
Choose HIMS Over TDOC NowBoth Hims & Hers and Teladoc Health carry a Zacks Rank #3 (Hold), indicating a balanced near-term outlook. However, current market positioning reflects a divergence in investor expectations around growth durability and execution risk. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hims & Hers appears to be priced with relatively balanced expectations following recent stock weakness. This suggests that a significant portion of near-term uncertainty — around margin pressures and category expansion — may already be reflected in the stock. For investors, this creates a potential opportunity if HIMS continues to scale its consumer platform, expand into high-demand categories and improve engagement through personalized, subscription-driven care. Its model is still in a growth phase, implying that upside is more closely tied to successful execution and sustained demand momentum.
Teladoc Health, in contrast, is being valued more conservatively, reflecting ongoing challenges in parts of its business, particularly within its direct-to-consumer mental health segment. While its integrated care platform, enterprise relationships and ongoing investments in technology provide a solid foundation, the market appears to be taking a more measured view on the pace of recovery and long-term growth visibility. This suggests that upside may depend on clearer signs of stabilization and consistent execution across segments.
While both companies present opportunities, Hims & Hers appears to offer relatively better upside at current levels, given its growth trajectory and the more favorable risk-reward balance implied by its current positioning.
Teladoc Health posts a y/y narrower Q1 loss and beats revenue estimates as international growth and cost cuts offset BetterHelp weakness and subscription declines.
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced its services are now available through Walmart's Better Care Services platform, expanding access to convenient, affordable care for customers. The collaboration brings Teladoc Health's suite of offerings – including virtual urgent care, dermatology, and nutrition services – to customers seeking both insured and cash-pay options.
Key Takeaways TDOC partnered with Walmart to offer virtual urgent care, dermatology and nutrition services.Walmart customers can access TDOC care for $89 per visit with insured and cash-pay options.TDOC services include 24/7 illness care, nutrition support and Walmart pharmacy fulfillment. Teladoc Health, Inc. (TDOC - Free Report) is widening its footprint in the U.S. virtual healthcare market through a new collaboration with Walmart’s Better Care Services platform. The partnership allows Walmart customers to access Teladoc’s virtual urgent care, dermatology and nutrition services, offering both insured and cash-pay options. The move strengthens TDOC’s efforts to expand affordable healthcare access while leveraging Walmart’s massive nationwide consumer network.
Under this partnership, Walmart customers can connect with healthcare providers for a cash-pay price of $89 per visit. Services include around-the-clock treatment for common illnesses such as flu symptoms, urinary tract infections and sinus infections, along with dermatology consultations and personalized nutrition support. Prescriptions can also be fulfilled through Walmart pharmacies, with same-day delivery available in several markets.
The partnership reflects a broader industry trend in which healthcare providers are teaming up with major retailers to make medical services more accessible and convenient for consumers. Teladoc Health has been expanding its presence across widely used consumer platforms, and Walmart’s extensive customer base may help the company strengthen its reach among uninsured and cost-conscious individuals. Earlier in 2026, Walmart also introduced TDOC’s BetterHelp mental health services on its Better Care Services platform.
It reflects how retailers are playing a larger role in healthcare delivery by expanding beyond traditional pharmacy services into virtual care and wellness support. Companies are increasingly building connected healthcare ecosystems that combine medical consultations, prescription access and preventive care solutions in one place. These partnerships could support broader adoption of telehealth services as companies seek more sustainable growth opportunities in an increasingly competitive market.
For Teladoc Health, the Walmart partnership could provide a key long-term growth catalyst as the company works to strengthen revenue momentum and expand consumer adoption. The ability to offer convenient care alongside pharmacy fulfillment may improve customer retention and recurring usage.
TDOC’s Price PerformanceOver the past year, TDOC shares have risen 7.6%, outperforming the industry’s decline of 0.8%.
Image Source: Zacks Investment Research
TDOC’s Zacks Rank & Key PicksTDOC currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the Medical space are Globus Medical, Inc. (GMED - Free Report) , Electromed, Inc. (ELMD - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.74 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. Globus Medical beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.3%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Electromed’s current-year earnings of $1.20 per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. Electromed beat earnings estimates in each of the trailing four quarters, with an average surprise of 20.1%. The consensus estimate for current-year revenues is pegged at $74 million, suggesting 15.6% year-over-year growth.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.64 per share has witnessed five upward revisions in the past 30 days, against no movement in the opposite direction. BrightSpring Health Services beat earnings estimates in three of the trailing four quarters and missed once, with an average surprise of 14.6%. The consensus estimate for current-year revenues is pegged at $15.1 billion, suggesting 16.6% year-over-year growth.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.
We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Teladoc Health, Inc. (NYSE: TDOC) breached their fiduciary duties to shareholders.
If you currently own Teladoc stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Teladoc Health (TDOC +0.41%) delivers virtual care worldwide; a key insider recently exited their stake, according to the latest SEC filing.
Fernando M. Rodrigues, President of BetterHelp, reported a direct open-market sale of 9,572 shares of Teladoc Health (TDOC +0.41%) valued at approximately $71,000, according to a SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)9,572Transaction value$70,833Post-transaction shares (direct)0Post-transaction value (direct ownership)$0Transaction value based on SEC Form 4 reported price ($7.40); post-transaction value based on June 3, 2026, market close ($7.09).
Key questionsHow does the size of this sale compare to Rodrigues's historical trading activity?
This sale of 9,572 shares is the largest of Rodrigues's two reported open-market sales, with the previous being 3,558 shares; it also aligns with a full divestment of the remaining direct holdings.What does the 100% disposition indicate about Rodrigues's ownership exposure?
The transaction reduces Rodrigues's direct and indirect common stock holdings to zero, eliminating his immediate equity exposure to Teladoc Health as of June 3, 2026.How did the stock perform around the transaction date?
Shares were priced at $7.40 at the market open and closed at $7.09 on June 3, 2026; over the preceding year, the stock returned -3.03% as of the transaction date, indicating relatively flat performance through the holding period.Company overviewMetricValuePrice (as of market close June 3, 2026)$7.40Market capitalization$1.27 billionRevenue (TTM)$2.51 billionNet income (TTM)($171.15 million)* 1-year performance is calculated using June 3, 2026, as the reference date.
Company snapshotOffers virtual healthcare services, including telehealth, chronic condition management, expert medical services, and mental health solutions under brands such as Teladoc, Livongo, and BetterHelp.Offers products and services under a platform-based model to employers, health plans, hospitals, health systems, insurance and financial services companies, and individual members.Serves a diverse client base, including employers, health insurers, hospitals, health systems, and individual members in the United States and internationally.Teladoc Health is a leading provider of virtual healthcare services, operating at scale with over 4,600 employees and a global footprint. The company’s strategy emphasizes comprehensive digital health solutions that integrate primary care, chronic disease management, and mental health offerings to address a broad spectrum of patient needs. Teladoc Health’s competitive advantage lies in its extensive platform, multi-specialty capabilities, and established relationships with large institutional customers.
What this transaction means for investorsThe President of BetterHealth, a wholly-owned subsidiary of Teladoc (TDOC), recently sold 9,572 shares of Teladoc stock, valued at approximately $71,000. Here are some key takeaways for investors.
First, Teladoc stock has struggled over the last three years. Shares have declined by 72% over this period, equating to a compound annual growth rate (CAGR) of -34.5%. That’s well below the S&P 500, which has generated a total return of nearly 80% over this same period, with a CAGR of 21.6%. Granted, Teladoc shares have stabilized recently, with shares down only 3% over the last 12 months.
Indeed, results have been mixed in recent months. In its latest earnings report, Teladoc beat revenue expectations, recording $614 million in first-quarter revenue. However, the company continues to struggle to turn a profit. Over the last 12 months, Teladoc’s net loss was ($171 million).
In summary, the stock remains in the midst of a restructuring, as the company shifts some of its focus away from a cash-pay model to an in-network, insurance model. If the company can pull off the transition, its 0.5x price-to-sales (P/S) ratio may appeal to some investors.
